India, China, and Japan are likely to fuel the growth of the global chronic idiopathic constipation market in Asia Pacific.Constipation can be defined as reduced stool frequency or difficulty in passing stool. Reduced or difficult stool passage includes hard lumpy stools, incomplete bowel movements, straining, incomplete evacuation, and need for manual removal of stool. have frequent constipation, corresponding to prevalence of 2%. Fleet Company, Inc.-based provider of syndicated research, customized research, and consulting services. Several factors contribute to constipation including change in water balance and motility in colon. Chronic idiopathic constipation (CIC) can be defined as more chronic or severe continuation of these above symptoms.Geographically, the global chronic idiopathic constipation treatment market has been segmented into five key regions: Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations. Often chronic idiopathic constipation is indicated with multiple symptoms. In terms of distribution channel, the market has been divided into independent pharmacies, drug stores, and hospital pharmacies. The infrequent bowel movement could be due to dry, hard stool leading to chronic idiopathic constipation. Major players in the global chronic idiopathic constipation treatment market include Boehringer Ingelheim GmbH, Bayer AG, C. If colon absorbs more water, the stool can be hard, dry, and difficult to pass. This slow movement results in more water absorption and leads to hard, dry bathroom footstools for sale stool. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications. Ltd. Mexico and Brazil are the high potential growth markets in Latin America because of improvement of medical infrastructure.Chronic idiopathic constipation occurs without an identifiable cause.transparencymarketresearch. It has been observed more common in adult aged or older people. In terms of type, the market has been segmented into pharmacological treatment and non-pharmacological treatment. Rising prescription opioid consumption, increasing geriatric population, rising health care expenditure, launch of targeted medicines, and growing awareness are likely to drive the chronic idiopathic constipation treatment market during the forecast period. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others.. If motility is slower down, the stool movement can be difficult to pass which results in infrequent bowel movement. Abbott Gut-Health Survey reported that 14% people in India suffer from constipation. The laxatives and stool softeners segments are expected to account for major share of the global chronic constipation market during the forecast period in comparison to other class of drugs.The frequency may be reduced to less than three times a week.S. As cause of constipation is unclear, it is called idiopathic constipation.php?flag. Pharmacological treatment consists of stool softener, laxatives, bulk forming agents, emollients, osmotic agents, chloride channel activators, and others. The report offers a comprehensive evaluation of the market. The data obtained from the National Center for Biotechnology Information revealed that 4 million people in the U. The rate at which muscles in colon contract to help pass through the stool is referred as motility., Daewoong Co. Increasing incidence, prevalence, and growing awareness can be considered the major factors driving the global chronic idiopathic constipation treatment market. A survey found chronic idiopathic constipation common in 56% women, 44% men. The projections featured in the report have been derived using proven research methodologies and assumptions. Many times the cause of constipation is unclear or unknown and not because of underlying illness or medication. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. Based on type of administration, the global chronic idiopathic constipation treatment market has been categorized into oral and parenteral. North America is expected to hold major share of the chronic idiopathic constipation treatment market owing to significant percentage of population suffering from CIC. Out of patients suffering from chronic idiopathic constipation only 12% are medically diagnosed and 40% are actively seeking treatment.transparencymarketresearch. The global chronic idiopathic constipation treatment market has been segmented based on type, type of administration, region, and distribution channel., Actavis, Ironwood Pharmaceuticals, Cosmo Pharmaceuticals, and Sucampo Pharmaceuticals, Inc. The repeatedly occurring most common symptoms include abdominal discomfort, bloating, gas pain, incomplete evacuation, hard stool, and straining at the time of bowel movement.Transparency Market Research (TMR) is a U. Europe was the second largest market for chronic idiopathic constipation treatment due to high prevalence rate.
ainertain...
ما را در سایت ainertain دنبال می کنید
برچسب : نویسنده : ainertain ainertain بازدید : 239 تاريخ : پنجشنبه 24 مرداد 1398 ساعت: 9:32